Atorvastatin, but Not Pravastatin, Inhibits Cardiac Akt/mTOR Signaling and Disturbs Mitochondrial Ultrastructure in Cardiac Myocytes
Overview
Authors
Affiliations
Statins, which reduce LDL-cholesterol by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are among the most widely prescribed drugs. Skeletal myopathy is a known statin-induced adverse effect associated with mitochondrial changes. We hypothesized that similar effects would occur in cardiac myocytes in a lipophilicity-dependent manner between 2 common statins: atorvastatin (lipophilic) and pravastatin (hydrophilic). Neonatal cardiac ventricular myocytes were treated with atorvastatin and pravastatin for 48 h. Both statins induced endoplasmic reticular (ER) stress, but only atorvastatin inhibited ERK1/2, Akt, and mammalian target of rapamycin signaling; reduced protein abundance of caveolin-1, dystrophin, epidermal growth factor receptor, and insulin receptor-β; decreased Ras homolog gene family member A activation; and induced apoptosis. In cardiomyocyte-equivalent HL-1 cells, atorvastatin, but not pravastatin, reduced mitochondrial oxygen consumption. When male mice underwent atorvastatin and pravastatin administration per os for up to 7 mo, only long-term atorvastatin, but not pravastatin, induced elevated serum creatine kinase; swollen, misaligned, size-variable, and disconnected cardiac mitochondria; alteration of ER structure; repression of mitochondria- and endoplasmic reticulum-related genes; and a 21% increase in mortality in cardiac-specific vinculin-knockout mice during the first 2 months of administration. To our knowledge, we are the first to demonstrate in vivo that long-term atorvastatin administration alters cardiac ultrastructure, a finding with important clinical implications.-Godoy, J. C., Niesman, I. R., Busija, A. R., Kassan, A., Schilling, J. M., Schwarz, A., Alvarez, E. A., Dalton, N. D., Drummond, J. C., Roth, D. M., Kararigas, G., Patel, H. H., Zemljic-Harpf, A. E. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes.
Cardiotoxicity as a Possible Side Effect of Statins.
Chaulin A Rev Cardiovasc Med. 2024; 24(1):22.
PMID: 39076865 PMC: 11270446. DOI: 10.31083/j.rcm2401022.
Alsmadi M, Abudaqqa A, Idkaidek N, Qinna N, Al-Ghazawi A AAPS PharmSciTech. 2024; 25(4):86.
PMID: 38605192 DOI: 10.1208/s12249-024-02803-z.
Somers T, Siddiqi S, Maas R, Sluijter J, Buikema J, van den Broek P Basic Res Cardiol. 2024; 119(2):309-327.
PMID: 38305903 DOI: 10.1007/s00395-023-01025-x.
The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin.
Chaulin A Life (Basel). 2023; 13(11).
PMID: 38004288 PMC: 10672543. DOI: 10.3390/life13112148.
Statins and Cardiomyocyte Metabolism, Friend or Foe?.
Somers T, Siddiqi S, Morshuis W, Russel F, Schirris T J Cardiovasc Dev Dis. 2023; 10(10).
PMID: 37887864 PMC: 10607220. DOI: 10.3390/jcdd10100417.